Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F8scFv
- Development stage
- Preclinical
- Lead developer
- Var2 Pharmaceuticals
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
F8scFv is a recombinant human single-chain variable fragment (scFv) antibody developed by Var2 Pharmaceuticals. It specifically targets oncofetal chondroitin sulfate (ofCS), a unique glycosaminoglycan modification found on a variety of proteoglycans across many different cancer types but absent from normal tissues. By binding to ofCS, F8scFv can be used as a targeting moiety for the delivery of therapeutic payloads (such as toxins in antibody-drug conjugates) or as a diagnostic tool. The drug is being investigated for a broad range of solid tumors, including colorectal, pancreatic, and lung carcinomas, as well as sarcomas like chondrosarcoma and osteosarcoma, where ofCS is highly expressed. F8scFv was identified through phage display and is designed to serve as a high-affinity targeting component for various therapeutic modalities.
- Other names
- F8 scFvF-8 scFvF 8 scFvanti-ofCS scFv clone F8
02
Targets
ofCS (Oncofetal chondroitin sulfate)
Beyond the preview
Go deeper on F8scFv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F8scFv.